OtoNexus Medical Technologies

OtoNexus Medical Technologies, Inc.Founded in 2010 in Seattle, US, OtoNexus Medical Technologies, Inc. develops groundbreaking medical devices aimed at diagnosing middle ear infections.OtoNexus Medical Technologies specializes in the development of a groundbreaking ultrasound otoscope designed for the rapid and accurate detection of middle ear infections, specifically acute otitis media. This innovative device leverages patented ultrasound technology, allowing clinicians to identify the presence of bacterial infections within the middle ear in as little as two seconds. The otoscope serves a critical function in healthcare by enabling healthcare providers to distinguish between viral and bacterial infections, thereby reducing unnecessary antibiotic prescriptions. The primary end users of this technology include healthcare professionals in various clinical settings, including pediatricians and family practice physicians, who are focused on improving patient outcomes related to middle ear infections.OtoNexus Medical Technologies operates a dual revenue model encompassing capital equipment sales and recurring income generated through the sale of disposable tips designed for its ultrasound otoscope. The transactions typically occur through direct sales to healthcare providers, including hospitals and clinics, facilitating a streamlined purchasing process. The company supports a model where customers purchase the otoscope and subsequently order one-time-use disposable tips that are necessary for each examination, enhancing hygiene and ensuring compliance with medical standards. This setup not only fosters a sustainable revenue stream but also reinforces the company's commitment to maintaining high hygiene standards in clinical environments. Plans for new product development are underway, with the goal of launching enhancements to the ultrasound otoscope that will better cater to healthcare professionals' needs.

1. Series C

   Apr 21, 2021

   Amount

   Undisclosed

   Investors

   Locked

2. Series B

   Oct 6, 2016

   Amount

   $3.5M

   Investors

   Locked